Coronary artery disease, hypertension, ApoE, and cholesterol: A link to Alzheimer's disease?

Annals of the New York Academy of Sciences

Volumn 826, Issue , 1997, Pages 128-146

  Larry Sparks, D ^a,b  

^a Div of Medical Examiner's Services   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; CHOLESTEROL;

ADULT; AGED; ALZHEIMER DISEASE; BRAIN LEVEL; COGNITION; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN TISSUE; HYPERTENSION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; RISK; SENILE PLAQUE;

EID: 9844226208     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1997.tb48466.x     Document Type: Conference Paper

References (92)

1. ALZHEIMER, A. 1987. A characteristic disease of the cerebral cortex. In The Early Story of Alzheimer's Disease. Translation of the Historical Papers. K. Bick, L. Amaducci, and G. Pepeu, Eds.: 1-3. Liviana Press. Florence, Italy.
2. KHACHATURIAN, Z. 1985. Diagnosis of Alzheimer's disease. Arch. Neurol. 42: 1097-1105.
3. SPARKS, D. L. et al. 1990. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol. Aging 11: 601-607.
4. SPARKS, D. L. et al. 1993. Temporal sequence of plaque formation in the cerebral cortex of non-demented individuals. J. Neuropath. Exp. Neurol. 52: 135-142.
5. SPARKS, D. L. et al. 1995. Increased density of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J. Neurol. Sci. 131: 162-169.
6. ARONSON, M. K. et al. 1990. Women, myocardial infarction, and dementia in the very old. Neurology 40: 1102-1106.
7. BRETELER, M. M. et al. 1994. Cardiovascular disease and distribution of cognitive function in elderly people: The Rotterdam Study. Br. Med. J. 308: 1604-1608.
8. PRINCE, M., M. CULLEN & A. MANN. 1994. Risk factor for Alzheimer's disease and dementia: A case-control study based on the MRC elderly hypertension trial. Neurology 44: 97-104.
9. LAUNER, L. J. et al. 1995. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia aging study. JAMA 274: 1846-1851.
10. SKOOG, I. et al. 1996. 15-year longitudinal study of blood pressure and dementia. Lancet 347: 1141-1145.
11. AGBAYEWA, M. 1986. Earlier psychiatric morbidity in patients with Alzheimer's disease. J. Am. Geriatr. Soc. 34: 561-564.
12. LICHTENBERG, P. A. et al. 1995. The relationship between depression and cognition in older adults: A cross-validation study. J. Gerontol. 50B: P25-P32.
13. TRESCH, D. et al. 1985. Prevalence and significance of cardiovascular disease and hypertension in elderly patients with dementia and depression. J. Am. Geriatr. Soc. 33: 530-537.
14. KUROSAWA, H. et al. 1983. The relationship between mental disorders and physical severities in patients with acute myocardial infarction. Jpn. Circ. J. 47: 723-728.
15. FRASURE-SMITH, N., F. LESPERANCE & M. TALAJIC. 1993. Depression following myocardial infarction: Impact on 6-month survival. JAMA 270: 1819-1825.
16. REICH, P. et al. 1983. Unrecognized organic mental disorders in survivors of cardiac arrest. Am. J. Psychiatry 140: 1194-1197.
17. CRYSTAL, H. et al. 1988. Clinicopathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 38: 1682-1687.
18. CORDER, E.H. et al. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.
19. MAYEUX, R. et al. 1993. The apolipoprotein E4 allele in patients with Alzheimer's disease. Ann. Neurol. 34: 752-754.
20. NALBANTOGLU, J. et al. 1994. Predictive value of apolipoprotein E genotyping in Alzheimer's disease: Results of an autopsy series and an analysis of several combined studies. Ann. Neurol. 36: 889-895.
21. POIRIER, J. et al. 1993. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342: 697-699.
22. REBECK, G. W. et al. 1993. Apolipoprotein E in sporadic Alzheimer's disease: Allelic Variation and receptor interactions. Neuron 11: 575-580.
23. SAUNDERS, A. M. et al. 1993. Association of apolipoprotein E allele e4 with late-onset familial and sporatic Alzheimer's disease. Neurology 43: 1467-1472.
24. WEISGRABER, K. H. 1994. Apolipoprotein E: Structure-function relationships. In Advances in Protein Chemistry.: 249-302. Academic Press. San Diego, CA.
25. CZECH, C. et al. 1994. Apolipoprotein E-4 gene dose in clinically diagnosed Alzheimer's disease: Prevalence, plasma cholesterol levels and cerebrovascular change. Eur. Arch. Psychiatry Clin. Neurosci. 243: 291-292.
26. KUUSISTO, J. et al. 1994. Association of apolipoprotein E phenotypes with late onset Alzheimer's disease: Population based study. Br. Med. J. 309: 636-638.
27. YOSHIZAWA, T. et al. 1994. Dose-dependent association of apolipoprotein E allele epsilon 4 with late-onset, sporadic Alzheimer's disease. Ann. Neurol. 36: 656-659.
28. AMOUYEL, P. et al. 1993. (Letter). Lancet 342: 1309.
29. DAVIGNON, J., R. E. GREGG & C. F. SING. 1988. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8: 1-21.
30. MAHLEY, R. W. 1988. Apolipoprotein E: Cholesterol transport protein with expanded role in cell biology. Science 240: 622-630.
31. SING, C. F. & J. DAVIGNON. 1985. Role of apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am. J. Hum. Genet. 37: 268-285.
32. UTERMANN, G. et al. 1984. Apolipoprotein E phenotypes and hyperlipidemia. Hum. Genet. 65: 232-236.
33. WILSON, P. W. F. 1995. Relation of high-density lipoprotein subfractions and apolipoprotein E isoforms to coronary disease. Clin. Chem. 41: 165-169.
34. METTER, E. J. & R. S. WILSON. 1993. Vascular Dementias.: 416-437. Oxford University Press. New York.
35. WARDEN, B. A. & E. THOMPSON. 1994. Apolipoprotein E and the development of atherosclerosis. Lab. Med. 25: 449-455.
36. WILSON, P. W. F. et al. 1994. Apolipoprotein E alleles, dyslipidemia and coronary heart disease. JAMA 272: 1666-1671.
37. ZHANG, S. H. et al. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258: 468-471.
38. GREGG, R. E. et al. 1986. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J. Clin. Invest. 78: 815-821.
39. GREGG, R. E. et al. 1989. Apolipoprotein E modulates the metabolism of apolipoprotein B containing lipoporteins by myltiple mechanisms. In Cholesterol Transport Systems and Their Relation to Atherosclerosis. R. Steinmetz, J. Kaffarnik, and H. Schneider, Eds.: 11-21. Springer-Verlag. Berlin/Heidelberg, Germany.
40. BOERWINKLE, E. & C. F. SING. 1987. The use of measured genotype information in the analysis of quantitative phenotypes in man. Ann. Hum. Genet. 51: 211-226.
41. CULLPEPPER, W. S. III, P. C. SODT & F. H. MESSERLI. 1983. Cardiac status in juvenile borderline hypertension. Ann. Intern. Med. 98: 1-7.
42. KLAG, M. J. et al. 1993. Serum cholesterol in young men and subsequent cardiovascular disease. N. Engl. J. Med. 328: 313-318.
43. 1984. INTER-SOCIETY COMMISSION FOR HEART DISEASE RESOURCES. Optimal resourses for primary prevention of atherosclerotic disease. Circulation 70: 153A-174A.
44. ESCARGUEIL-BLANC, I., R. SALVAYRE & A. NEGRE-SALVAYRE. 1994. Necrosis and apoptosis induced by oxidized low density lipoproteins occur through two calcium-dependent pathways in lymphoblastoid cells. FASEB J. 8: 1075-1080.
45. BRIDGES, A. B. et al. 1992. Relationship between the extent of coronary artery disease and indicators of free radical activity. Clin. Cardiol. 15: 169-174.
46. SHARMA, R. C. et al. 1992. Immunolocalization of native antioxidant scavenger enzymes in early hypertensive and atherosclerotic arteries. Arteriosclerosis and Thrombosis 12: 403-415.
47. SPARKS, D. L. et al. 1994. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126: 88-94.
48. SPARKS, D. L. et al. 1995. Increased density of cortical apolipoprotein E immunoreactive neurons in rabbit brain after dietary administration of cholesterol. Neurosci. Lett. 187: 142-144.
49. SPARKS, D. L. 1996. Intraneuronal β-amyloid immunoreactivity in the CNS. Neurobiol. Aging 17: 291-299.
50. KITA, T. et al. 1987. Probucol prevents the progression of atherosclerosis in Watanabe familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA 84: 5928-5931.
51. GHINEA, N. et al. 1987. Prelesional events in atherogenosis. Changes induced by hypercholesterolemia in the cell surface chemistry of arterial endothelium and blood monocytes, in rabbit. J. Submicrosc. Cytol.: 209-227.
52. SCHWARTZ, C. J. et al. 1992. Atherosclerosis: Potential targets for stabilization and regression. Circulation 86: 117-123.
53. YLA-HERTTUALA, S. et al. 1989. Evidence for the presence of oxidately modified low density lipoproterin in atherosclerotic lesions of rabbit and man. J. Clin. Invest 84: 1086-1095.
54. SPARKS, D. L. 1997. Dietary cholesterol induces Alzheimer-like β-amyloid immunoreactivity in rabbit brain. In Cholesterol Metabolism and Brain Function. Nutr. Metab. Cardiovasc. Dis. (Suppl.) In press.
55. HSIAO, K. et al. 1996. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274: 99-102.
56. DIETSCHY, J. M. 1997. Overview of cholesterol and lipoprotein metabolism in the brain, liver and extrahepatic organs. In Cholesterol Metabolism and Brain Function. Nutr. Metab. Cardiovasc. Dis. (Suppl.) 7: in press.
57. DOBBING, J. 1963. Entry of cholesterol into rat brain during development. J. Neurochem. 10: 739-742.
58. SEROUGNE, C., C. LEFEVRE & F. CHEVALLIER. 1976. Cholesterol transfer between brain and plasma in the rat: A model for the turnover of cerebral cholesterol. Exp. Neurol. 51: 229-240.
59. TRUDY, S. D., J. M. ANDERSON & J. M. DIETSCHY. 1981. Rates of sterol synthesis and uptake in the major organs of the rat in vivo. J. Lipid. Res. 22: 551-569.
60. HAGUE, Z. U. & Z. MOZAFOR. 1992. Importance of dietary cholesterol for the maturation of mouse brain myelin. Biosci. Biotech. Biochem. 56: 1351-1354.
61. LEHTONEN, A. & S. LUUTONEN. 1986. High-density lipoprotein cholesterol levels of very old people in the diagnosis of dementia. Age and Aging 15: 267-270.
62. KOZACHUK, W. E. et al. 1990. White matter hyperintensities in dementia of Alzheimer's type and in healthy subjects without cerebrovascular risk factors. Arch. Neurol. 47: 1306-1310.
63. BOYLES, J. K. et al. 1989. A role for apolipoprotein E, apolipoprotein A-1, and low density lipoprotein receptor in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J. Clin. Invest. 83: 1015-1031.
64. STRITTMATTER, W. et al. 1993. Apolipoprotein E: High affinity binding to beta-amyloid and increased frequency of type-4 allele in late-onset familial Alzheimer's. Proc. Natl. Acad. Sci. USA 90: 1977-1981.
65. STRITTMATTER, W. J., A. M. SAUNDERS & M. GOEDERT. 1994. Isoform specific interactions of apolipoprotein E with microtubule-associated protein tau: Implications for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 91: 11183-11186.
66. NAMBA, Y. et al. 1991. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541: 163-166.
67. ZHANG, S. et al. 1994. Dietary cholesterol inhibits whole-body but not cerebrum cholesterol synthesis in young pigs. J. Nutr. 124: 717-725.
68. TURLEY, S. D. et al. 1996. Brain does not utilize low density lipoprotein-cholesterol during fetal and neonatal development in the sheep. J. Lipid. Res. 37: 1953-1961.
69. SPADY, D. K. & J. M. DIETSCHY. 1983. Sterol synthesis in vivo in 18 tissues of the squirrel, monkey, guinea pig, rabbit, hamster and rat. J. Lipid Res. 24: 303-315.
70. TINT, G. S. et al. 1994. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N. Engl. J. Med. 330: 107-113.
71. TINT, G. S. 1996. Mental retardation and cholesterol synthesis in the brain. In Cholesterol Metabolism and Brain Function. Nutr. Metab. Cardiovasc. Dis. (Suppl.) In press.
72. MASON, R. P. et al. 1992. Evidence for changes in the alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol. of Aging 13: 413-419.
73. KITSON, N. et al. 1994. A model membrane approach to the epidermal permeability barrier. Biochemistry 33: 6707-6715.
74. JOHNSON, D. A., F. VALENZUELA & R. ZIDOVETZKI. 1992. A deuterium NMR and steady-state fluorescence anisotropy study of the effects of cholesterol on the lipid membrane-disordering actions of ethanol. Biochem. Pharm. 44: 769-774.
75. SEVANIAN, A. & L. MCLEOD. 1987. Cholesterol autoxidation in phospholipid membrane bilayers. Lipids 22: 627-636.
76. KUTRYK, M. J., B. R. MADDAFORD & G. N. PIERCE. 1991. Oxidation of membrane cholesterol alters active and passive transsarcolemmal calcium movement. Circ. Res. 68: 18-26.
77. MATTSON, M. P. et al. 1992. β-amyloid peptides destabilize calcium homoeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12: 376-389.
78. MARKESBERY, W. R., M. A. LOVELL & W. D. EHMANN. 1994. Increased lipid peroxidation and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurobiol. Aging 15: S139-S140.
79. DELACOURTE, A., et al. 1988. Preferential localization of copper zinc Superoxide dismutase in the vulnerable cortical neurons in Alzheimer's disease. Neurosci. Lett. 92: 247-253.
80. VOLICER, L. & P. B. CRINO. 1990. Involvement of free radicals in dementia of the Alzheimer type: A hypothesis. Neurobiol. Aging 11: 567-571.
81. RICHARDSON, J. S., K. V. SUBBARAO & L. C. ANG. 1992. On the possible role of iron-induced free radical peroxidation in neuronal degeneration in Alzheimer's disease. Ann. N. Y. Acad. Sci. 648: 326-327.
82. CEBALLOS, I. et al. 1991. Neuronal localization of copper-zinc Superoxide dismutase protein and mRNA within the human hippocampus from control and Alzheimer's disease brains. Free Rad. Res. Comm. 12-13: 571-580.
83. PAPPOLLA, M. A. et al. 1992. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease. Am. J. Pathol. 140: 621-628.
84. SUBBARAO, K., S. RICHARDSON & L. ANG. 1990. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J. Neurochem. 55: 342-345.
85. JEANDEL, C., et al. 1989. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 35: 275-282.
86. BRUGGE, K. L. et al. 1992. The role of alterations in free radical metabolism in mediating cognitive impairments in Down's syndrome. Birkhauser Verlag. Basal Switzerland.: 190-197.
87. HIXSON, J. E. & D. T. VERNIER. 1990. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31: 545-548.
88. LIU, K., T. E. CUDDY & G. N. PEIRCE. 1992. Oxidative status of lipoproteins in coronary disease patients. Am. Heart J. 123: 285-290.
89. UUSITUPA, M. et al. 1994. Apolipoprotein E phenotype and blood pressure. Lancet 353: 57.
90. HOF, P. R. et al. 1995. Age-related distribution of neuropathologic changes in the cerebral cortex of Down syndrome cases: Quantitative regional analysis and comparison with Alzheimer's disease. Arch. Neurol. 52: 379-391.
91. SPARKS, D. L. & J. C. HUNSAKER. 1992. Down's syndrome: Occurrence of ALZ-50 reactive neurons and the formation of senile plaques. J. Neurol. Sci. 109: 77-82.
92. SPARKS, D. L. 1997. Vascular related and mediated alterations in Alzheimer's disease. In Cerebral Cortex, Vol. 14. J. Morrison and A. Peters, Eds. Raven Press. New York. In press.